Table Plan and attendees



First Name Surname Job Title Company
Mario Alberto Accardi Venture Partner Vita Advisory
Khatereh Ahmadi Executive Director, BD&L MSD
Debra Ainge COO Clinigen
Paul Airley Partner Fladgate LLP
Jeff Almond Vistiing Fellow, Oxford Martin University of Oxford
Richard Anderson Managing Partner SCIAD Communications
Joao Andrade CEO WideCells Group Plc
Mike Anstey Investment Director Cambridge Innovation Capital
Jessica Archer Global HR Director Clinigen
Will Arends Partner Marks & Clerk
Sakae Asanuma President Taiho Ventures, LLC
Paul Ashley Head of Technology Transfer - Life Sciences Oxford University Innovation Ltd.
Holly Austen-Davies Corporate Partnerships Manager  Alzheimer's Research UK
Dani Bach Director, Healthcare Ventures Touchstone Innovations
Trevor Baglin Founder ApcinteX & SuperX
Marcus Baker Director Rothschild & Co.
Gil Bar-Nahum Managing Director Jefferies
Raymond Barlow CEO e-Therapeutics plc
Gemma Barrett Senior Associate Bristows LLP
Shabnam Bashir Associate Director Citigate Dewe Rogerson
Sarah Batey Project Director F-star Biotechnology
John Beadle CEO PsiOxus Therapeutics
Phil Beales CMO Congenica
Hani Bekdash Lawyer - Contract Specialist Faber, Daeufer and Itrato
Deborah Bell Junior Account Manager Instinctif Partners
Andy Bentham Partner JA Kemp
Stefan Berg Managing Director EQS Group
Maina Bhaman Director, Healthcare Ventures Touchstone Innovations
Veronique Birault Head of Translation Francis Crick Institute
Wesley Blackaby VP, Chemistry Storm Therapeutics Ltd
Phil Bland-Ward CSO Crescendo Biologics
Edward Bliss General Counsel and Company Secretary LifeArc
Keith Blundy Chief Executive Officer Storm Therapeutics Ltd
Chas Bountra Professor of Translational Medicine University of Oxford
John Bradshaw Independent Non-Executive Director CREO Medical
Matt Bratton Senior Inward Investment Executive Invest Newcastle
David Bridgland CFO WideCells Group Plc
David Briggs Division Director Arthur J Gallagher
Jack Brownrigg Head of Research Capital Cell
John Burt CFO Abzena
Richard Butt CEO Apollo Therapeutics
Ewa Campbell CMO Biotech and Money
Jeremy Carmichael VP Corporate Development Head of Business Development  Astex Pharmaceuticals
Tom Cavanagh CEO Oxular
Sue Charles Managing Partner, Life Sciences Instinctif Partners
Shaun Chilton CEO Clinigen
Wang Chong Partner and Head of Corporate Finance Shard Capital Partners
Mary Clark CEO iR
Simon Clayton Commercial Director Clinigen
Sarah Cole European Investment Director Takeda Ventures
Yuehua Cong Business Development F-star Biotechnology
Ed Corbett Principal Novasecta
Andrew Craig Partner WG Partners
Richard Craven General Counsel CREO Medical
Jeremy Curnock Cook Managing Director BioScience Managers
Josh Dance SVP Biotech and Money
Jane Dancer CBO F-star Biotechnology
Neil Darkes Co-CEO Biotech and Money
John Dawson CEO Oxford BioMedica (UK)
Michel de Baar Executive Director, BD&L MSD
Robert de Jonge Director, Business Development Tusk Therapeutics
Darrin Disley Chief Executive Officer Horizon Discovery
Clive Dix Non-Executive Carrick Therapeutics
Luc Dochez CEO Tusk Therapeutics
Leanne Dronfield Clinical Project Manager Nightstar Therapeutics
Maciek Drozdz Principal, Venture Investments Johnson & Johnson
Victoria Durrans Business Analyst BioScience Managers
Glyn Edwards Chief Executive Officer Summit Therapeutics plc
Jon Edwards Principal Medicxi
Mark Farmer Co-Founder  Eden Ventures
Richard Fazackerley Group Supply Chain Director Clinigen
Laura Ferguson Director, UK Capital Cell
Isobel Finnie Partner Haseltine Lake
Laura Fletcher Associate Director CRT
Louise Fordham Senior Analyst Biotech and Money
Russell Gardiner Marketing Executive Biotech and Money
Rowena Gardner Head of Operations and Company  Microbiotica
Lopes Gil COO WideCells Group Plc
Miruna Girtu Strategic Partnerships Manager Syndicate Room
Malcolm Glaister CEO 8GT Fund
Steve Glass CCO Clinigen
Chris Golden Director, Healthcare Corporate Finance Peel Hunt
Richard Goodfellow CEO Scancell Holdings
Nigel Gordon Partner Fladgate LLP
Shaun Grady Vice President, Global Business Development  AstraZeneca
Gary Green Partner CMS
Alan Greenberg Non Executive Director & SVP WideAcademy WideCells Group Plc
Tobias Greven Head of Legal Business Development Merck
Conor Griffin Managing Director Hume Brophy
Andrew Griggs Senior Partner, Audit, Advisory and Corporate Finance Kreston Reeves
Craig Gulliford CEO CREO Medical
Colin Hailey Partner Confluence Tax
Timothy Haines Managing Partner Abingworth
Matthew Hall CFO Tusk Therapeutics
James Halstead Corporate Partner Covington & Burling
Chris Hancock CTO CREO Medical
Sarah Hanson Partner CMS
Theo Harold CFO Crescendo Biologics
Gemma Harris Account Director Instinctif Partners
Tolga Hassan CFO F-star Biotechnology
John Haurum CEO F-star Biotechnology
Adrian Hayday Scientific Director GammaDelta Therapeutics Limited
Olav Hellebo CEO ReNeuron
Richard Hennings Commercial Director Verona Pharma plc
Graham Hertrich UK Equity Capital Markets Advisory KPMG
Tony Hickson Managing Director, Technology Transfer Imperial Innovations
Graham Hine Non-Executive Chairman WideCells Group Plc
Lena Hodge Partner Brown Rudnick
Jessica Hodgson Associate Partner Consiliium Strategic Communications
Dayle Hogg COO GammaDelta Therapeutics Limited
Asaf Homossany Managing Director, EMEA Nasdaq
Iain Hopper Director, Life Sciences & Digital Health Bailey Fisher
David Horner Of Counsel Bristows LLP
Camilla Hume Corporate Finance, Growth Companies Cenkos Securities
Martin Hunt Chairman SkinBioTherapeutics
Jim Huntington Founder ApcinteX & SuperX
Alicia Irurzun-Lafitte Principal Merck Ventures
Catherine Isted Healthcare Specialist Sales Peel Hunt
Steve Jackson Frederick James Quick Professor of Biology, The Gurdon Institute University of Cambridge
Marcus Jackson Director, Corporate Broking RBC Capital Markets
Felicity James Corporate Partnerships Officer Alzheimer's Research UK
Harren Jhoti CEO Astex Pharmaceuticals
Michael Johnson Growth Companies, Corporate Broking Cenkos Securities
Nigel Jones Managing Director Circadian Therapeutics
Matthew Jones CCO Dyadic International
Viviane Joynes Managing Director EQS Group
Dan Kemp Senior Director Takeda Pharmaceuticals
Liz Klein Investment Consultant BioScience Managers
Peter Krantz CEO Multipharma
Olga Krylova Senior Director, Global Scouting Pfizer Limited
Phil L'Huillier Head of Business Development, Europe MSD
Bridget Lacay Business Development Director Circassia
Vicky Lake Corporate Partnerships Manager  Alzheimer's Research UK
Charles Large CEO Autifony
Margaret Larkin SVP, Finance Carrick Therapeutics
Bobby Leach VP Group Corporate Affairs Convatec
Nick Lench COO Congenica
Richard Lewis Investment Director Downing
Tim Luker Senior Director, Emerging Technology & Innovation Eli Lilly and Company
Anker Lundemose CEO MISSION Therapeutics
David Luther CFO MISSION Therapeutics
Stefan Luzi Associate Gilde Healthcare Partners
Fiona MacLaughlin Director Inkef Capital
Sunjay Malhotra Corporate Associate Covington & Burling
Priya Mande COO PsiOxus Therapeutics
Sacha Mann CEO BiosysHealth
Kostas Manolis Partner Downing
Niall Martin CEO Artios Pharma Ltd
Alex Martinez Non-Executive Director Biotech and Money
Niall McAlister Partner CMS
Alison McGhee Head of Intellectual Property F-star Biotechnology
Sophie McGrath Partner Brown Rudnick
Raj Mehta Director of IP GammaDelta Therapeutics Limited
Amanda Miller General Counsel Clinigen
Chris Molloy CEO Medicines Discovery Catapult
Nicholas Moore Senior Vice President Jefferies
Natalie Mount CSO GammaDelta Therapeutics Limited
Andrew Muncey CFO Artios Pharma Ltd
Marzena Murawska Clinical Project Manager Nightstar Therapeutics
Julie Nahid Rahman Healthcare and Private Equity Practices Spencer Stuart
Lindsey Neville Consultant Consiliium Strategic Communications
Ian Newman Senior Associate Hill Dickinson LLP
Kenneth Newman CMO Verona Pharma plc
Ian Nicholson Chief Executive F2G Ltd
Mo Noonan Senior Director FTI Consulting
Oliver Nussbaumer Founder and Head of Cell Research GammaDelta Therapeutics Limited
Michael O'Brien Accounts and Outsourcing Partner, Head of Technology Kreston Reeves
Terry O'Dwyer Co-CEO Biotech and Money
Karolina Osmak Business Support Assistant NewcastleGateshead Initiative
Paolo Paoletti CEO GammaDelta Therapeutics Limited
Kyri Papantoniou Partner, Corporate Fletcher Day
Ash Patel Investment Manager Mercia Technologies
Maria Patey Account Executive SCIAD Communications
Daniel Pavin Partner Covington & Burling
Marine Perrier Account Manager Citigate Dewe Rogerson
Marek Petecki Partner Bristows LLP
Marina Petroca Partner Covington & Burling
Catherine Pickering CEO and Founder iOnctura
Emma Pickup Account Executive SCIAD Communications
Carolyn Porter Head of the Pharma and Biotech Team  Oxford University Innovation Ltd
Eddie Powell Partner Fladgate LLP
Aubrey Powell Corporate Finance Director N+1 Singer
Matt Pullan SVP, Business Development Biotech and Money
Richard Pye Sr Director, Corporate Affairs and Communications Summit Therapeutics plc
Doug Quinn CFO SkinBioTherapeutics
Iain Redford Partner Bristows LLP
Damian Reece Managing Partner Instinctif Partners
Richard Rees CFO CREO Medical
David  Reynolds Chief Scientific Officer Alzheimer's Research UK
Andy Richards Chairman Congenica
Martin Ridler Senior Financial Advisor and Board Member Multipharma
Tom Roberts VP, BD and Memberships Biotech and Money
Alan Robson Relationship Director Barclays
Rogier Rooswinkel Principal Forbion
John Rountree Partner Novasecta
Marco Schwartz Head of Equity Capital Markets KPMG
Tony Sedgwick Board Member  Blueberry Therapeutics
Graziano Seghezzi Managing Partner Sofinnova Partners
Taz Shariff VP, LifeStars Biotech and Money
Alex Shaw Managing Partner, Life Sciences Instinctif Partners
Mike Shaw Director of IP & Licensing King's College London
James Shaw Co-Founder JAG Shaw Baker
Kristian  Shearsby Associate Covington & Burling
Marianne Shepherd Associate Marks & Clerk
Hanna Skeppner Director FTI Consulting
Michael Skynner VP Operations Bicycle Therapeutics
Claire Smith Marketing & BD Executive Bristows LLP
Owen Smith Investment Manager Arix Bioscience
Lucy Squance Director of Supporter-led Fundraising  Alzheimer's Research UK
Susanna Stanfield Partner JAG Shaw Baker
Nick Staples CBO Artios Pharma Ltd
Nick Stephens The RSA Group The RSA Group
Thomas Stockman Managing Director RBC Capital Markets
Guy Strutton Global Head of HR Business Partnering Clinigen
Elaine Sullivan CEO Carrick Therapeutics
Ashley Tapp Associate Director, Life Sciences Instinctif Partners
Iain Thomas Head of Life Science Cambridge Enterprise
Michael Thomas Associate Director Arthur J Gallagher
Navin Thomas Marketing Manager Biotech and Money
Richard Thompson Senior Investment Executive Finance Wales
Brandon Thompson Associate Covington & Burling
Jonathan Tobin Investment Manager Arix Bioscience
Ian Tomlinson Chairman Apollo Therapeutics
Melanie Toyne-Sewell Managing Partner, Life Sciences Instinctif Partners
Mandy Tribe Executive Assistant Clinigen
Simon Turner Managing Partner Alacrita
Richard Vellacott Chief Financial Officer Horizon Discovery
Joke Vereecken Investment Associate Droia Oncology Ventures
Samantha Vieira Senior Director of Programme Management Nightstar Therapeutics
Guillaume Vignon Global Head of Immuno-Oncology Licensing & Business Development Merck
Emily Vipond VP, Invetors Relations and Development Biotech and Money
Sandra von Meier Director Business Development Oncology Global Business Development Merck
Phil Walker Head of Healthcare, Corporate Finance Zeus Capital
Anthony  Walker Managing Partner Alacrita
Henno Welgemoed Medical Director Clinigen
Marc Wilkinson Partner JA Kemp
Erik Woolgar Partner Shard Capital Partners
Dafydd Wright Managing Partner The RSA Group